From local player to global market leader and consolidator in the market of pharmaceutical compounding.
Fagron was founded in Rotterdam (the Netherlands) in 1990. Through a continuous focus on innovation, quality and solution-oriented thinking, Fagron obtained market leadership in pharmaceutical compounding in the Netherlands in just 7 years. Fagron’s successful strategy of optimizing and innovating customized pharmaceutical care in order to widen the therapeutic options of prescribers worldwide and improving patients’ quality of life. Its unique business model and the investments in innovation and product development resulted in the fact that Fagron is currently leading in pharmaceutical compounding and is active in 32 countries in Europe, the Americas, the Middle East, Africa, Asia and the Pacific. Fagron products and innovations are sold to over 200,000 customers in over 60 countries around the world.
Fagron is active in the following segments of pharmaceutical compounding:
- Fagron Compounding Services: customized medication that is prepared in Fagron’s sterile and non-sterile compounding facilities in Europe, North America, South America and South Africa.
- Fagron Brands: innovative concepts, vehicles and formulations for pharmaceutical compounding that are developed by Fagron, often in close cooperation with prescribers, pharmacies and universities.
- Fagron Essentials: pharmaceutical raw materials, equipment and supplies that pharmacists need in order to be able to prepare medication in the pharmacy.
With over 2,000 employees Fagron generated turnover of € 422 million in 2016. In 2017, Fagron will further reinforce its worldwide market leadership based on an active buy-and-build strategy and organic growth.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam (the Netherlands).